Papers by Srisakun Sinsawad
Health science journal, 2019
Objective: To determine efficacy of non-bisphosphonate drugs for preventing osteoporotic vertebra... more Objective: To determine efficacy of non-bisphosphonate drugs for preventing osteoporotic vertebral fracture in postmenopausal women by systematic review and meta-analysis. Methods: Published reports were searched through the electronic databases including MEDLINE and the Cochran Library (CENTRAL) from inception to November 2015. Randomized controlled trial (RCT) studies on efficacy of non-bisphosphonate drugs including denosumab, raloxifene, strontium ranelate, teriparatide and tibolone compared with placebo and/or calcium plus vitamin D with the outcome of incidence of vertebral fracture were selected. Results of pooled efficacy from meta-analysis were presented as risk ratio (RR) with 95% confident interval (CI). Results: The search identified 12 articles consistent with inclusion criteria. The studies compared effects of non-bisphosphonates with placebo for 1 - 3 years.It was found that denosumab, strontium ranelate and teriparatide significantly prevented vertebral fracture with...
Objective: To estimate the efficacy of bisphosphonates in preventing osteoporotic fractures in po... more Objective: To estimate the efficacy of bisphosphonates in preventing osteoporotic fractures in postmenopausal women systematic review and meta-analysis. Methods: Published reports were searched through electronic database including MEDLINE and the Cochrane Library from inception to November 2015. We selected randomized controlled trials (RCTs) examining efficacy of bisphosphonates compared with placebo and/or calcium plus vitamin D with outcomes of incidence of bone fracture. Results: Sixteen RCTs with duration of 1 – 3 years met the eligibility criteria. Meta-analysis showed that alendronate (5 - 10 mg/day) and risedronate (2.5 and 5 mg/day) could prevent vertebral fracture by 45% (RR = 0.55; 95% CI: 0.46, 0.67) and 38% (RR = 0.62; 95% CI: 0.51, 0.75), respectively. Alendronate, risedronate and zoledronate (5 mg/day) could prevent non-vertebral fractures by 15% (RR = 85; 95% CI: 0.75, 0.97), 19% (RR = 0.81; 95% CI: 0.72, 0.90) and 24% (RR = 0.76; 95% CI: 0.66, 0.88), respectively.T...
Uploads
Papers by Srisakun Sinsawad